

Име и презиме		Милене М. Јуришевић				
Звање		Доцент				
Назив институције у којој наставник ради са пуним радним временом и од када		Факултет медицинских наука, Универзитет у Крагујевцу		2012.		
Ужа научна односно уметничка област		Клиничка фармација				
Академска каријера						
	Година	Институција	Област			
Избор у звање	2019.	Факултет медицинских наука, Универзитет у Крагујевцу	Клиничка фармација			
Докторат	2019.	Факултет медицинских наука, Универзитет у Крагујевцу	Медицина			
Специјализација						
Магистратура						
Диплома	2011.	Факултет медицинских наука, Универзитет у Крагујевцу	Фармација			
Репрезентативне референце						
1.	Minic Janicijevic S, Jovanovic IP, Gajovic NM, Jurisevic MM, Debnath M, Arsenijevic NN, Borovcanin MM. Galectin-3 mediated risk of inflammation in stable schizophrenia, with only possible secondary consequences for cognition. <i>World J Psychiatry</i> . 2022;12(9):1183-1193.					
2.	Milosevic J, Jurisevic M, Grbovic V, Jovanovic I, Gajovic N, Jurisic-Skevin A. Potential Protective Role of Galectin-3 in Patients with Gonarthrosis and Diabetes Mellitus: A Cross-Sectional Study. <i>Int J Environ Res Public Health</i> . 2022;19(18):11480.					
3.	Jovićić Milić SS, Jevtić VV, Radislavljević SR, Petrović BV, Radojević ID, Raković IR, Petrović ĐS, Stojković DL, Jurišević M, Gajović N, Petrović A, Arsenijević N, Jovanović I, Klisurić OR, Vuković NL, Vukić M, Kačaniová M. Synthesis, characterization, DNA interactions and biological activity of new palladium(II) complexes with some derivatives of 2-aminothiazoles. <i>J Inorg Biochem</i> . 2022;233:111857.					
4.	Jocić M, Arsenijević N, Gajović N, Jurišević M, Jovanović I, Jovanović M, Zdravković N, Marić V, Jovanović M. Anemia of inflammation in patients with colorectal cancer: Correlation with interleukin-1, interleukin-33 and galectin-1. <i>J Med Biochem</i> . 2022;41(1):79-90.					
5.	Markovic SS, Gajovic N, Jurisevic M, Jovanovic M, Jovicic BP, Arsenijevic N, Mijailovic Z, Jovanovic M, Dolicanin Z, Jovanovic I. Galectin-1 as the new player in staging and prognosis of COVID-19. <i>Sci Rep</i> . 2022;12(1):1272.					
6.	Jovanovic MM, Jurisevic MM, Gajovic NM, Arsenijevic NN, Jocic MV, Jovanovic IP, Zdravkovic ND, Djukic AL, Maric VJ, Jovanovic MM. Increased Severity of Ulcerative Colitis in the Terminal Phase of the Metabolic Syndrome. <i>Tohoku J Exp Med</i> . 2021;254(3):171-182.					
7.	Petrovic Dj, Jovicic Milic S, Djukic M, Radojevic I, Jelic R, Jurisevic M, Radic G, Gajovic N, Arsenijevic N, Jovanovic I, Markovic N, Stojkovic D, Jevtic V. Synthesis, characterization, HSA/DNA binding, cytotoxicity study, and antimicrobial activity of new palladium(II) complexes with some esters of (S,S) propylenediamine-N,N'-di-2-(3-methyl)butanoic acid. <i>Inorganica Chimica Acta</i> . 2021;528:120601.					
8.	Jocic M, Gajovic N, Jurisevic M, Jovanovic M, Zdravkovic N, Arsenijevic N, Vukovic Dejanovic V, Maric V, Milev B, Jovanovic M. Colorectal carcinoma: evaluation of systemic values of interleukin-1 and interleukin-33 in patients with and without thrombocytosis. <i>Vojnosanit pregl</i> . 2021;78(6): 627-634.					
9.	Jovanovic-Stevic S, Cacic D, Puchta R, Bogojeski J, Jurisevic M, Gajovic N, Jakovljevic S, Arsenijevic N, Jovanovic I, Petrovic B. Assessment of biological activity of the caffeine-derived Pt(II) and Pd(II) complexes. <i>Appl Organomet Chem</i> . 2021; doi.org/10.1002/aoc.6532.					
10.	Sekulic Markovic S, Jovanovic M, Gajovic N, Jurisevic M, Arsenijevic N, Jovanovic M, Jovanovic M, Mijailovic Z, Lukic S, Zornic N, Vukicevic V, Stojanovic J, Maric V, Jovicic M and Jovanovic I. IL-33 Correlates With COVID-19 Severity, Radiographic and Clinical Finding. <i>Frontiers in Medicine</i> . 2021;8:749569. doi: 10.3389/fmed.2021.749569.					
11.	Jovanovic M, Geller D, Gajovic N, Jurisevic M, Arsenijevic N, Jovanovic M, Supic G, Vojvodica D, Jovanovic I. Dual blockage of PD-L/PD-1 and IL33/ST2 axes slows tumor growth and improves antitumor immunity by boosting NK cells. <i>Life Sci</i> . 2022;289:120214.					
12.	Konovalov B, Franich A, Jovanović M, Jurisević M, Gajović N, Jovanović M, Arsenijević N, Maric V, Jovanović I, Živković M Rajković S. Synthesis, DNA/BSA-binding affinity and cytotoxicity of dinuclear platinum(II) complexes with 1,6-naphthyridine bridging ligand. <i>Appl Organomet Chem</i> 2020; doi: 10.1002/aoc.6112.					
13.	Benazic S, Silconi ZB, Jevtovic A, Jurisevic M, Milovanovic J, Mijailovic M, Nikolic M, Kanjevac T, Potočnák I, Samořová E, Ratkovic ZR, Radic G, Milovanovic M, Pantic J, Arsenijevic N, Radosavljevic GD. The Zn(S-pr-thiosal)2 complex attenuates murine breast cancer growth by inducing apoptosis and G1/S cell cycle arrest. <i>Future Med Chem</i> . 2020;12(10):897-914.					
14.	Borovcanin MM, Minic Janicijevic S, Jovanovic IP, Gajovic NM, Jurisevic MM, Arsenijevic NN. Type 17 Immune Response Facilitates Progression of Inflammation and Correlates with Cognition in Stable Schizophrenia. <i>Diagnostics (Basel)</i> . 2020;10(11):926.					
15.	Bošković M, Franich A, Rajković S, Jovanović M, Jurisević M, Gajović N, Jovanović M, Arsenijević N, Jovanović I and Živković M. Potential antitumor effect of newly synthesized dinuclear 1,5-naphthyridine-bridging palladium(II) complexes. <i>ChemistrySelect</i> . 2020;5:10549-10555.					
16.	Lukic R, Cupic M, Gajovic N, Jurisevic M, Mijailovic Z, Davidovic B, Kujundzic B, Joksimovic B, Arsenijevic N, Jovanovic I. Increased systemic sST2 in patients with end stage renal disease contributes to milder liver damage during HCV infection. <i>J Infect Dev Ctries</i> . 2020;14(5):519-526.					
17.	Jovanovic M, Simovic Markovic B, Gajovic N, Jurisevic M, Djukic A, Jovanovic I, Arsenijevic N, Lukic A, Zdravkovic N. Metabolic syndrome attenuates ulcerative colitis: Correlation with interleukin-10 and galectin-3 expression. <i>World J Gastroenterol</i> . 2019;25(43):6465-6482.					
18.	Jovanovic M, Gajovic N, Jurisevic M, Simovic Markovic B, Maric V, Jovanovic M, Arsenijevic N, Zdravkovic N. Fecal sST2 correlates with disease severity of ulcerative colitis. <i>Vojnosanit Pregl</i> . 2019;76(11):1153-1161.					
19.	Jurisevic M, Jagic N, Gajovic N, Arsenijevic A, Jovanovic M, Milovanovic M, Pantic J, Jovanovic I, Sabo T, Radosavljevic G, Arsenijevic N, O,O'-diethyl-(S,S)-ethylenediamine-N,N'-di-2-(3-cyclohexyl)propanoate dihydrochloride enhances influx of effective NK and NKT cells in murine breast cancer. <i>Vojnosanit Pregl</i> . 2020;77:715-723.					
20.	Pavlovic M, Gajovic N, Jurisevic M, Mitrović S, Radosavljevic G, Pantic J, Arsenijevic N, Jovanovic I. Diverse Expression of IL-32 in Diffuse and Intestinal Types of Gastric Cancer. <i>Gastroenterol Res Pract</i> . 2018;2018:6578273.					
21.	Pavlovic M, Jurisevic M, Gajovic N, Mitrović S, Jovanovic M, Radosavljevic G, Pantic J, Radovanovic D, Arsenijevic N, Jovanovic I. IL-32 expression associates with lymph vessel invasion in intestinal type of gastric cancer. <i>Vojnosanit Pregl</i> . 2020;77:816-825.					
22.	Besser Silconi Z, Benazic S, Milovanovic J, Jurisevic M, Djordjevic D, Nikolic M, Mijailovic M, Ratkovic Z, Radic G, Radislavljevic S, Petrovic B, Radosavljevic G, Milovanovic M, Arsenijevic N. DNA binding and antitumor activities of platinum (IV) and zinc (II) complexes with some S-alkyl derivatives of thiosalicylic acid. <i>Transit Met Chem</i> . 2018;43:719-729.					
23.	Gajovic N, Jurisevic M, Pantic J, Radosavljevic G, Arsenijevic N, Lukic ML, Jovanovic I. Attenuation of NK cells facilitates mammary tumor growth in streptozotocin-induced diabetes in mice. <i>Endocr Relat Cancer</i> . 2018;25(4):493-507.					
24.	Jovanovic M, Gajovic N, Zdravkovic N, Jovanovic M, Jurisevic M, Vojvodic D, Maric V, Arsenijevic A, Jovanovic I. Fecal Galectin-3: A New Promising Biomarker for Severity and Progression of Colorectal Carcinoma. <i>Mediators Inflamm</i> . 2018;2018:8031328.					
25.	Jovanovic M, Gajovic N, Zdravkovic N, Jovanovic M, Jurisevic M, Vojvodic D, Mirkovic D, Milev B, Maric V, Arsenijevic N. Fecal galectin-1 as a potential marker for colorectal cancer and disease severity. <i>Vojnosanit Pregl</i> . 2019;76(10):1037-1044.					
26.	Lukic R, Gajovic N, Jovanovic I, Jurisevic M, Mijailovic Z, Maric V, Popovska Jovicic B, Arsenijevic N. Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients. <i>Dis Markers</i> . 2017;2017:6275987.					
27.	Projovic I, Vukadinovic D, Milovanovic O, Jurisevic M, Pavlovic R, Jacovic S, Jankovic S, Stefanovic S. Risk factors for potentially inappropriate prescribing to older patients in primary care. <i>Eur J Clin Pharmacol</i> . 2016;72(1):93-107.					

28.	Jakovljevic MM, Lazarevic M, Jurisevic M, Jovanovic MR. When cure becomes an illness-abuse of addictive prescription medicines. <i>Front Pharmacol.</i> 2015;6:193.
29.	Jakovljevic MB, Djordjevic N, Jurisevic M, Jankovic S. Evolution of the Serbian pharmaceutical market alongside socioeconomic transition. <i>Expert Rev Pharmacoecon Outcomes Res.</i> 2015;15(3):521-30.
30.	Kovacevic A, Dragojevic-Simic V, Rancic N, Jurisevic M, Gutzwiller F, Matter-Walstra K, Jakovljevic M. End-of-life costs of medical care for advanced stage cancer patients. <i>Vojnosanit Pregl.</i> 2015;72(4):334-41.
31.	Boskovic M, Djokovic J, Grubor I, Guzvic V, Jakovljevic B, Jurisevic M, Ljubisic D, Mijajlovic M, Milicevic I, Milovanovic M, Nikolic L, Nikolic M, Peric S, Petrovic A, Petrovic J, Radonjic K, Simonovic L, Simovic M, Stojanovic S, Stojic I, Tomovic J, Vranic S, Vucicevic K, Zdravkovic A, Jankovic S. PhD students' awareness of research misconduct. <i>J Empir Res Hum Res Ethics.</i> 2013;8(2):163-4.
32.	Jurisevic M, Arsenijevic A, Pantic J, Gajovic N, Milovanovic J, Milovanovic M, Poljarevic J, Sabo T, Vojvodic D, Radosavljevic GD, Arsenijevic N. The organic ester O,O'-diethyl-(S,S)-ethylenediamine-N,N'-di-2-(3-cyclohexyl)propanoate dihydrochloride attenuates murine breast cancer growth and metastasis. <i>Oncotarget.</i> 2018;9(46):28195-28212.
33.	Jurisevic M, Radosavljevic G, Arsenijevic A, Milovanovic M, Gajovic N, Djordjevic D, Milovanovic J, Stojanovic B, Ilic A, Sabo T, Kanjevac T. Platinum complexes with edda (ethylenediamine-N,N'-diacetate) ligands as potential anticancer agents. <i>Serb J Exp Clin Res.</i> 2016;17(4):285-95.

Збирни подаци научне, односно уметничке и стручне активности наставника

Укупан број цитата	Science Citation Index, Web of Science		
	Scopus		
Укупан број радова са SCI или (SSCI) листе	31		
Тренутно учешће на пројектима	4	Домаћи	4
		Међународни	
Усавршавања			
Други релевантни подаци			